Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Sensus Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Sensus Healthcare wird ein Gewinn- und Umsatzwachstum von 30.9% bzw. 15.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 29.3% pro Jahr wachsen soll.

Wichtige Informationen

30.9%

Wachstumsrate der Gewinne

29.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	15.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 11

Recent updates

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

May 12

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Apr 16

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 11

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Oct 17

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Jul 04

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Mar 14

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

May 11

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

Apr 29

Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality

Apr 01

Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?

Dec 17

We Discuss Why Sensus Healthcare, Inc.'s (NASDAQ:SRTS) CEO Compensation May Be Closely Reviewed

May 30

Sensus Healthcare: Likely Post-Pandemic Sales Recovery Can Boost Share Price

Apr 26

Analysts Expect Breakeven For Sensus Healthcare, Inc. (NASDAQ:SRTS) Before Long

Apr 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SRTS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	42	8	N/A	N/A	1
12/31/2024	31	3	N/A	N/A	2
3/31/2024	32	5	-5	-4	N/A
12/31/2023	24	0	-2	-2	N/A
9/30/2023	25	-1	-15	-15	N/A
6/30/2023	30	2	-12	-12	N/A
3/31/2023	38	6	-11	-10	N/A
12/31/2022	45	24	-2	-1	N/A
9/30/2022	44	27	7	7	N/A
6/30/2022	41	25	4	4	N/A
3/31/2022	34	21	4	4	N/A
12/31/2021	27	4	0	0	N/A
9/30/2021	19	0	1	1	N/A
6/30/2021	15	-2	-3	-3	N/A
3/31/2021	11	-4	-2	-2	N/A
12/31/2020	10	-7	-1	0	N/A
9/30/2020	13	-7	0	0	N/A
6/30/2020	17	-6	1	1	N/A
3/31/2020	24	-3	5	5	N/A
12/31/2019	27	-2	-3	-2	N/A
9/30/2019	27	-3	-5	-4	N/A
6/30/2019	27	-2	-5	-5	N/A
3/31/2019	26	-3	-13	-12	N/A
12/31/2018	26	-2	-9	-9	N/A
9/30/2018	25	-3	-7	-6	N/A
6/30/2018	23	-3	-5	-5	N/A
3/31/2018	22	-3	-4	-4	N/A
12/31/2017	21	-4	N/A	-3	N/A
9/30/2017	19	-3	N/A	-2	N/A
6/30/2017	18	-2	N/A	-3	N/A
3/31/2017	16	-2	N/A	-3	N/A
12/31/2016	15	0	N/A	-1	N/A
9/30/2016	14	0	N/A	-2	N/A
6/30/2016	13	0	N/A	-1	N/A
3/31/2016	11	0	N/A	-1	N/A
12/31/2015	10	-1	N/A	-1	N/A
9/30/2015	8	-2	N/A	-1	N/A
12/31/2014	6	-4	N/A	-2	N/A
12/31/2013	10	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SRTSDas prognostizierte Gewinnwachstum (30.9% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: SRTSDie Erträge des Unternehmens (30.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: SRTSEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: SRTSDie Einnahmen des Unternehmens (15.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: SRTSDie Einnahmen des Unternehmens (15.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SRTS in 3 Jahren voraussichtlich hoch sein wird

Sensus Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Price target decreased by 29% to US$10.90

Consensus EPS estimates fall by 14%

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$15.30

Recent updates

Independent Director recently sold US$123k worth of stock

Investor sentiment improves as stock rises 69%

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare Announces Directors Changes

Sensus Healthcare, Inc. to Report Q4, 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

New major risk - Earnings quality

Investor sentiment improves as stock rises 31%

Sensus Healthcare, Inc. (NasdaqCM:SRTS) announces an Equity Buyback for $3 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations

New major risk - Share price stability

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Independent Director recently bought US$60k worth of stock

Investor sentiment deteriorates as stock falls 37%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 29% to US$10.90

Full year 2022 earnings: EPS misses analyst expectations

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Investor sentiment deteriorates as stock falls 17%

Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?

Now 20% undervalued

Consensus EPS estimates fall by 14%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS misses analyst expectations

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sensus Healthcare, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Insufficient new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Sensus Healthcare, Inc. Introduces Silk(TM) Laser Hair Removal System

Now 23% undervalued

Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger

Now 21% undervalued

President & General Counsel notifies of intention to sell stock

Investor sentiment improved over the past week

Co-Founder recently sold US$521k worth of stock

Sensus Healthcare, Inc. Appoints Mohammad K. Khan to Medical Advisory Board

Now 22% undervalued

Co-Founder notifies of intention to sell stock

Independent Director recently sold US$710k worth of stock

Sensus Healthcare, Inc. Launches Upgrade to its SRT-100 Vision System with New Ultrasound Capabilities

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.017 loss in 2Q 2021)

Sensus Healthcare Q2 GAAP EPS, revenue beats

Investor sentiment improved over the past week

Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month

Independent Director recently sold US$75k worth of stock

Consensus revenue estimates increase by 21%

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

Price target increased to US$13.20

Insufficient new directors

Investor sentiment deteriorated over the past week

Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality